138 related articles for article (PubMed ID: 12041527)
1. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Apisarnthanarak A; Little JR; Tebas P
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041527
[No Abstract] [Full Text] [Related]
2. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Ullmann AJ; Heussel CP; Cornely OA
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526
[No Abstract] [Full Text] [Related]
3. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever.
Powers JH; Dixon CA; Goldberger MJ
N Engl J Med; 2002 Jan; 346(4):289-90. PubMed ID: 11807157
[No Abstract] [Full Text] [Related]
4. Decisions about voriconazole versus liposomal amphotericin B.
Walsh TJ; Lee J; Dismukes WE
N Engl J Med; 2002 May; 346(19):1499; author reply 1499. PubMed ID: 12000825
[No Abstract] [Full Text] [Related]
5. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Johnson JR
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12037157
[No Abstract] [Full Text] [Related]
6. Empirical antifungal therapy--new options, new tradeoffs.
Marr KA
N Engl J Med; 2002 Jan; 346(4):278-80. PubMed ID: 11807153
[No Abstract] [Full Text] [Related]
7. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
[TBL] [Abstract][Full Text] [Related]
8. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
9. Treating disseminated fusariosis: amphotericin B, voriconazole or both?
Ho DY; Lee JD; Rosso F; Montoya JG
Mycoses; 2007 May; 50(3):227-31. PubMed ID: 17472622
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
[TBL] [Abstract][Full Text] [Related]
11. Successful management of invasive aspergillosis with voriconazole and amphoteracin B therapy in a patient with acute mycloid leukemia (AML-M2).
Manzoor NF; Azim S; Fadoo Z
J Pak Med Assoc; 2010 Nov; 60(11):977-9. PubMed ID: 21375212
[TBL] [Abstract][Full Text] [Related]
12. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.
Consigny S; Dhedin N; Datry A; Choquet S; Leblond V; Chosidow O
Clin Infect Dis; 2003 Jul; 37(2):311-3. PubMed ID: 12856225
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
[TBL] [Abstract][Full Text] [Related]
14. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole versus amphotericin B for invasive aspergillosis.
Blot F; Edé C; Nitenberg GM
N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12490695
[No Abstract] [Full Text] [Related]
16. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
17. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
Pagano L; Valentini CG; Fianchi L; Caira M
J Chemother; 2011 Feb; 23(1):5-8. PubMed ID: 21482486
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough invasive pulmonary aspergillosis despite empirical voriconazole therapy for febrile neutropenia: case report and review of the literature.
Meyer M; Waldvogel S; Chalandon Y; Bongiovanni M; Pache JC; Van Delden C
Scand J Infect Dis; 2007; 39(8):731-3. PubMed ID: 17654353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]